1. Home
  2. GCTK vs CERO Comparison

GCTK vs CERO Comparison

Compare GCTK & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GCTK
  • CERO
  • Stock Information
  • Founded
  • GCTK 2001
  • CERO 2017
  • Country
  • GCTK United States
  • CERO United States
  • Employees
  • GCTK N/A
  • CERO N/A
  • Industry
  • GCTK Medical/Dental Instruments
  • CERO
  • Sector
  • GCTK Health Care
  • CERO
  • Exchange
  • GCTK Nasdaq
  • CERO Nasdaq
  • Market Cap
  • GCTK 7.6M
  • CERO 8.5M
  • IPO Year
  • GCTK N/A
  • CERO N/A
  • Fundamental
  • Price
  • GCTK $0.24
  • CERO $0.06
  • Analyst Decision
  • GCTK
  • CERO
  • Analyst Count
  • GCTK 0
  • CERO 0
  • Target Price
  • GCTK N/A
  • CERO N/A
  • AVG Volume (30 Days)
  • GCTK 557.4K
  • CERO 33.3M
  • Earning Date
  • GCTK 11-14-2024
  • CERO 11-19-2024
  • Dividend Yield
  • GCTK N/A
  • CERO N/A
  • EPS Growth
  • GCTK N/A
  • CERO N/A
  • EPS
  • GCTK N/A
  • CERO N/A
  • Revenue
  • GCTK N/A
  • CERO N/A
  • Revenue This Year
  • GCTK N/A
  • CERO N/A
  • Revenue Next Year
  • GCTK N/A
  • CERO N/A
  • P/E Ratio
  • GCTK N/A
  • CERO N/A
  • Revenue Growth
  • GCTK N/A
  • CERO N/A
  • 52 Week Low
  • GCTK $0.20
  • CERO $0.05
  • 52 Week High
  • GCTK $4.95
  • CERO $12.80
  • Technical
  • Relative Strength Index (RSI)
  • GCTK 23.92
  • CERO 39.14
  • Support Level
  • GCTK $0.20
  • CERO $0.05
  • Resistance Level
  • GCTK $0.32
  • CERO $0.21
  • Average True Range (ATR)
  • GCTK 0.03
  • CERO 0.02
  • MACD
  • GCTK 0.06
  • CERO -0.01
  • Stochastic Oscillator
  • GCTK 24.45
  • CERO 14.60

About GCTK GlucoTrack Inc.

GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

Share on Social Networks: